KMT2A and leukemia: Although this discovery has led to a clinical trial of the DOT1L inhibitor EPZ-5676 for the treatment of leukemias harboring a rearrangement of the MLL gene, existing DOT1L inhibitors did not sufficiently suppress breast tumor growth and metastasis in an earlier study [20].